ADARx Pharmaceuticals, Inc. (ADRX) - What Are Investment Firms Thinking About This Stock?

Key Points

  • Analysts are moderately bullish: Four of five covering firms rate ADRx a buy, while one rates it a hold; the average 12-month price target is $35.
  • ADRx shares opened at $14, within their 52-week range of $12.50 to $23.21. The company reported quarterly EPS of -$1.74, missing the -$0.40 consensus estimate.
  • Insiders have been buying: Company insiders purchased 3.26 million shares worth about $55.4 million over the past 90 days, and Goldman Sachs disclosed a new position of 181,300 shares.
  • Five stocks to consider instead of ADARx Pharmaceuticals.

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $35.00.

A number of brokerages recently weighed in on ADRX. TD Cowen began coverage on ADARx Pharmaceuticals in a research note on Tuesday, October 20th. They set a "buy" rating for the company. Zacks Research raised ADARx Pharmaceuticals to a "hold" rating in a research report on Wednesday, October 21st. JPMorgan Chase & Co. began coverage on ADARx Pharmaceuticals in a research note on Tuesday, October 20th. They issued an "overweight" rating and a $38.00 target price on the stock. Wall Street Zen upgraded shares of ADARx Pharmaceuticals to a "hold" rating in a report on Saturday, October 3rd. Finally, UBS Group initiated coverage on shares of ADARx Pharmaceuticals in a report on Tuesday, October 20th. They issued a "buy" rating and a $35.00 target price for the company.

Read Our Latest Stock Report on ADRX

ADARx Pharmaceuticals Price Performance

Shares of NASDAQ:ADRX opened at $14.00 on Tuesday. ADARx Pharmaceuticals has a 52 week low of $12.50 and a 52 week high of $23.21.

ADARx Pharmaceuticals (NASDAQ:ADRX - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($1.34). On average, equities analysts predict that ADARx Pharmaceuticals will post -2.03 EPS for the current fiscal year.

Insider Activity

In other news, Director Erez Chimovits acquired 61,516 shares of the business's stock in a transaction dated Monday, September 28th. The shares were purchased at an average price of $17.00 per share, with a total value of $1,045,772.00. Following the transaction, the director directly owned 9,292,025 shares in the company, valued at approximately $157,964,425. This represents a 0.67% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Simeon George acquired 1,600,000 shares of the business's stock in a transaction dated Monday, September 28th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $27,200,000.00. Following the transaction, the director owned 5,554,094 shares in the company, valued at approximately $94,419,598. The trade was a 40.46% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have bought 3,261,516 shares of company stock worth $55,445,772.

Institutional Investors Weigh In On ADARx Pharmaceuticals

A hedge fund recently bought a new position in ADARx Pharmaceuticals stock. Goldman Sachs Group Inc. purchased a new position in shares of ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 181,300 shares of the company's stock, valued at approximately $3,615,000. Goldman Sachs Group Inc. owned approximately 0.17% of ADARx Pharmaceuticals at the end of the most recent quarter.

ADARx Pharmaceuticals Company Profile

(Get Free Report)

ADARx Pharmaceuticals is a clinical-stage biopharmaceutical company developing RNA-targeted medicines for serious diseases. Its research focuses on oligonucleotide therapeutics designed to alter the activity of specific RNA molecules and, in turn, address disease-related gene expression. The company's pipeline includes investigational candidates for conditions such as hereditary angioedema and complement-mediated diseases. These therapies remain in development and have not been established as approved treatments.

Featured Stories

Analyst Recommendations for ADARx Pharmaceuticals (NASDAQ:ADRX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ADARx Pharmaceuticals Right Now?

Before you consider ADARx Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADARx Pharmaceuticals wasn't on the list.

While ADARx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines